• L&C Bio’s third-quarter 2026 operating profit rose 239.8% year over year to KRW 9.84 billion.
• Revenue increased 70.4% from a year earlier to KRW 38.45 billion.
• Net income reached KRW 4.9 billion, reversing a year-earlier loss of KRW 51.34 billion.
• For the first nine months of 2026, operating profit jumped 892.1% to KRW 24.42 billion.
• The nine-month net loss narrowed 69.1% to KRW 20.5 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. L&C Bio Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261109900320), on November 09, 2026, and is solely responsible for the information contained therein.